Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

80.65GBp
8:56am EDT
Change (% chg)

1.20 (+1.51%)
Prev Close
79.45
Open
77.45
Day's High
80.75
Day's Low
77.45
Volume
401,227
Avg. Vol
4,475,802
52-wk High
127.22
52-wk Low
68.00

Chart for

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.41
Market Cap(Mil.): £705.16
Shares Outstanding(Mil.): 679.34
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -- -- --
ROI: -- 15.07 14.61
ROE: -- 16.60 16.34

BRIEF-Sosei Says Does Not Intend To Make An Offer For Vectura

* CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR VECTURA

Apr 24 2018

BRIEF-Vectura Says CFO Decided To Leave Group

* CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR ANDREW DERODRA HAS DECIDED TO LEAVE GROUP

Apr 20 2018

CORRECTED-UPDATE 1-UK's Vectura posts wider 2017 loss, revenue rise

March 21 British drugmaker Vectura reported a worse-than-expected pretax loss for the full year on Wednesday, dragged by lower royalties and higher costs related to the SkyePharma deal.

Mar 21 2018

BRIEF-Vectura Group Posts FY Reported Revenue Of 148.0 Mln Pounds‍​

* FULL YEAR REPORTED REVENUE OF £148.0 MILLION, IN LINE WITH BOARD EXPECTATIONS (REPORTED 9M 2016: £126.5 MILLION)‍​

Mar 21 2018

Earnings vs. Estimates